

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising: (a) a HMG CoA reductase inhibitor; (b) ~~a vitamin B6 related compound~~ pyridoxal 5'-phosphate; and (c) a pharmaceutically acceptable carrier.

2. (Original) The pharmaceutical composition according to claim 1 wherein the HMG CoA reductase inhibitor is selected from a group consisting: pravastatin, lovastatin, fluvastatin, atorvastatin, simvastatin, rosuvastatin, velostatin, fluindostatin, and a mixture thereof.

3-7 (Cancelled)

8. (Currently Amended): A method for treating a patient at risk of cardiovascular disease comprising administering a therapeutically effective dose of the pharmaceutical composition according to ~~any one of claims 1 to 7~~ claim 1.

9. (Original) The method according to claim 8, wherein the patient is susceptible to hepatotoxicity.

10 (Currently Amended) The method according to claim 8 wherein the cardiovascular disease is selected from a group consisting: congestive heart failure, myocardial ischemia, arrhythmia, myocardial infarction, ischemic stroke, hemorrhagic stroke, coronary artery disease, hypertension (~~high blood pressure~~), atherosclerosis (~~clogging of the arteries~~), aneurysm, peripheral artery disease (PAD), thrombophlebitis (~~vein inflammation~~), diseases of the heart lining, diseases of the heart muscle, carditis, congestive heart failure, endocarditis, ischemic heart disease, valvular heart disease (~~malfunction of a valve or valves in the blood vessels of the heart~~), arteriosclerosis (~~hardening of the arteries~~), acute coronary syndrome (ACS), deep vein thrombosis (DVT), Kawazaki disease, high cholesterol, restinosis, late vein graft failure and heart transplant.

11. (Original) The method according to claim 8 wherein the dose of the HMG CoA reductase inhibitor is between 0.1 and 1000 mg per day.
12. (Original) The method according to claim 8 wherein the dose of the HMG CoA reductase inhibitor is 10 mg per day.
13. (Original) The method according to claim 8 wherein the dose of the HMG CoA reductase inhibitor is 20 mg per day.
14. (Currently Amended) The method according to claim 8 wherein the dose of the ~~vitamin-B6 related compound~~ pyridoxal 5'-phosphate is between 0.1 to 50 mg/kg per day.
15. (Currently Amended) The method according to claim 8 wherein the dose of ~~vitamin-B6 related compound~~ pyridoxal 5'-phosphate is between 1 to 15 mg/kg per day.
16. (Currently Amended) A method of treating a patient at risk for diabetes comprising administering a therapeutically effective dose of the pharmaceutical composition according to ~~any one of claims 1 to 8~~ claim 1.
17. (Currently Amended) A method for treating a patient at risk of Alzheimer's disease comprising administering a therapeutically effective dose of the pharmaceutical composition according to ~~any one of claims 1 to 8~~ claim 1.
18. (Currently Amended) A method for treating a patient at risk of osteoporosis comprising administering a therapeutically effective dose of the pharmaceutical composition according to ~~any one of claims 1 to 8~~ claim 1.
19. (Currently Amended) A method of treating ~~or preventing~~ hypercholesterolemia in a patient, comprising administering a therapeutically effective dose of a ~~vitamin-B6 related compound~~ wherein the ~~vitamin-B6 related compound~~ is selected from a group consisting: pyridoxal-5'-phosphate, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal 4,5-aminal, a pyridoxine phosphate analogue, and a mixture thereof.

20 - 23 (Cancelled)

24. (Currently Amended) A method for treating a patient at risk of cardiovascular disease, said patient being administered a HMG CoA reductase inhibitor, comprising administering a therapeutically effective dose of ~~a vitamin B6 related compound~~ pyridoxal 5'-phosphate and a pharmaceutically acceptable carrier.

25. (Original): The method according to claim 24 wherein the HMG CoA reductase inhibitor is selected from a group consisting: pravastatin, lovastatin, fluvastatin, atorvastatin, simvastatin, rosuvastatin, velostatin, fluindostatin, and a mixture thereof.

26 - 30 (Cancelled)

31. (Currently Amended) The method according to ~~any one of claims 24 to 30~~ claim 24 wherein the patient is susceptible to hepatotoxicity.

32. (Currently Amended) The method according to ~~any one of claims 24 to 31~~ claim 24 wherein the cardiovascular disease is selected from a group consisting: congestive heart failure, myocardial ischemia, arrhythmia, myocardial infarction, ischemic stroke, hemorrhagic stroke, coronary artery disease, hypertension (~~high blood pressure~~), atherosclerosis (~~clogging of the arteries~~), aneurysm, peripheral artery disease (PAD), thrombophlebitis (~~vein inflammation~~), diseases of the heart lining, diseases of the heart muscle, carditis, congestive heart failure, endocarditis, ischemic heart disease, valvular heart disease (~~malfunction of a valve or valves in the blood vessels of the heart~~), arteriosclerosis (~~hardening of the arteries~~), acute coronary syndrome (ACS), deep vein thrombosis (DVT), Kawazaki disease, high cholesterol, restinosis, late vein graft failure and heart transplant.

33. (Currently Amended) The method according to ~~any one of claims 24 to 32~~ claim 24 wherein the dose of the HMG CoA reductase inhibitor is between 0.1 and 1000 mg per day.

34. (Currently Amended) The method according to ~~any one of claims 24 to 32~~ claim 24 wherein the dose of the HMG CoA reductase inhibitor is 10 mg per day.

35. (Currently Amended) The method according to ~~any one of claims 24 to 32~~ claim 24 wherein the dose of the HMG CoA reductase inhibitor is 20 mg per day.

36. (Currently Amended) The method according to ~~any one of claims 24 to 32~~ claim 24 wherein the dose of ~~the vitamin B6 related compound~~ pyridoxal 5'-phosphate is between 0.1 to 50 mg/kg per day.

37. (Currently Amended) The method according to ~~any one of claims 24 to 32~~ claim 24 wherein the dose of ~~the vitamin B6 related compound~~ pyridoxal 5'-phosphate is between 1 to 15 mg/kg per day.